Physician profile
Daniela Agnew
NPI 1700274354
$2,659.26
in general payments reported to CMS, 2019-2025
32 companies · $155 in 2025
The $155 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,060 · 2022: $908 · 2023: $423 · 2024: $114 · 2025: $155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $691.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $691.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $414.08 | 2021-2022 | |
| Novo Nordisk INC | $320.52 | 2021-2025 | Rybelsus, Ozempic |
| Novartis Pharmaceuticals Corporation | $223.02 | 2021-2022 | |
| Lilly USA, LLC | $179.33 | 2022-2025 | Mounjaro, Jardiance, Emgality |
| Astrazeneca Pharmaceuticals LP | $159.61 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $148.29 | 2022 | |
| Janssen Pharmaceuticals, INC | $129.07 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $113.41 | 2021-2025 | |
| Abbvie INC. | $107.14 | 2021-2023 | Ubrelvy |
| E.R. Squibb & Sons, L.L.C. | $99.30 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.69 | 2021-2023 | Spiriva Respimat, Stiolto Respimat, Tradjenta |
| Pfizer INC. | $84.76 | 2021-2023 | |
| Antares Pharma, INC. | $64.78 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $45.23 | 2023 | Quviviq |
| Amgen INC. | $39.63 | 2024 | Repatha, Otezla |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $37.70 | 2024-2025 | Doc Band |
| Glaxosmithkline, LLC. | $37.18 | 2021-2022 | |
| Hikma Pharmaceuticals USA | $36.85 | 2021-2022 | |
| Abbott Laboratories | $35.86 | 2022-2024 | Octrode |
| Biohaven Pharmaceuticals, INC. | $30.16 | 2021 | |
| Avion Pharmaceuticals | $29.32 | 2021-2022 | |
| Inspire Medical Systems, INC. | $29.17 | 2023 | Inspire |
| Phadia US INC. | $23.71 | 2024 | Immunocap |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.13 | 2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $22.44 | 2023 | Verquvo, Segluromet, Belsomra |
| Xeris Pharmaceuticals, INC. | $21.75 | 2025 | Gvoke Hypopen |
| Impel Pharmaceuticals INC. | $21.04 | 2022 | |
| Amarin Pharma, INC. | $21.02 | 2021 | |
| Medtronic, INC. | $19.60 | 2025 | Inceptiv |
| Hologic Sales and Service, LLC | $18.78 | 2023 | Thinprep 2000 Processor |
| Eyevance Pharmaceuticals LLC | $14.99 | 2021 | |
| Itamar Medical INC | $10.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniela Agnew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.